Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • EN
  • 中文
  • 한국어
  • 日本語
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
EPO Enlarged Board of Appeal set to consider in G 1/23 the degree to which enablement impacts the status of a commercially available product as state of the art

EPO Enlarged Board of Appeal set to consider in G 1/23 the degree to which enablement impacts the status of a commercially available product as state of the art

by Carolyn Haywood | Aug 11, 2023 | EPO

Background to the referral The referral comes from Board 3.3.03 in the consideration of T 0438/19, an appeal against the decision of the opposition division to reject an opposition against European patent no. 2626911 directed to a material for encapsulating a solar...
Not all epitopes are equal: patent rights in antibodies for challenging targets.

Not all epitopes are equal: patent rights in antibodies for challenging targets.

by David Eyre | May 25, 2023 | EPO

In laboratory practice the production of new antibodies is now often considered routine with a desired epitope synthesised and used to raise antibodies to that specific sequence. Accordingly under European practice the EPO views generating antibodies against any known...
The UKIPO confirms that an SPC is for the product in the marketing authorisation on which it is based and not further uses for the product

The UKIPO confirms that an SPC is for the product in the marketing authorisation on which it is based and not further uses for the product

by David Eyre | Feb 27, 2023 | UK

In this decision the Hearing Officer noted that a marketing authorisation is focused on what a product is rather than what it does. Consequently, a change in how the authorised product is used does not alter the basis of the original marketing authorisation....
New Referral to the Enlarged Board of Appeal on the Use of Post-Published Data to Support Inventive Step Confirmed

New Referral to the Enlarged Board of Appeal on the Use of Post-Published Data to Support Inventive Step Confirmed

by Sean Hutchinson | Feb 8, 2022 | EPO

Background In our previous article, we discussed the expected referral to the Enlarged Board of Appeal in case T 116/18, wherein the Board of Appeal decided greater clarity was required concerning the use of post-published data when considering inventive step. The...
A New Standard for Submitting Protein and Nucleic Acid Sequences – “ST.26”

A New Standard for Submitting Protein and Nucleic Acid Sequences – “ST.26”

by David Eyre | May 1, 2021 | US & International

Up until now, there has been an international system for disclosing nucleic acid and proteins sequences in a format that can be used by patent offices for searching and examination of patent applications. This system is administered by the World Intellectual Property...
« Older Entries
Next Entries »

Search

Recent Posts

  • Squeezed Out! AstraZeneca overturns Wyeth’s $107.5M Infringement Award
  • UPC Court of Appeal Confirms Lock-in Danger
  • When “Monotherapy” Means Monotherapy: A Cautionary Tale on Claim Interpretation and Added Matter at the EPO
  • Has the EPO TBA Demolished the Essentiality Test?
  • A Clear Way Forward for Description Amendments: Decision Issued in G 1/25

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.